1,238 filings
6-K
SNY
Sanofi
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
S-8 POS
SNY
Sanofi
15 Mar 24
Registration of securities for employees (post-effective amendment)
8:40am
6-K
SNY
Sanofi
27 Feb 24
Current report (foreign)
11:35am
IRAN
SNY
Sanofi
23 Feb 24
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
2:02pm
6-K
SNY
Sanofi
15 Feb 24
Current report (foreign)
12:09pm
SC 13G/A
vzzvhmnt
14 Feb 24
Sanofi / Amundi ownership change
3:57pm
SC 13G/A
y3dmftfelzh
13 Feb 24
Sanofi / DODGE & COX ownership change
1:55pm
SC 13G/A
j0tl7 cai79glj
6 Feb 24
Sanofi / BlackRock ownership change
3:14pm
6-K
dbda04w1f7gt5omlakr
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
h1unxd x1z
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
8vxlm hoiu9bd5p5
23 Jan 24
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
7:23am
6-K
9amop
17 Jan 24
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
1:49pm
6-K
2ka7m53tut57i
27 Dec 23
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
11:18am
6-K
evlu8zy5vkgjyrbzcxzt
20 Dec 23
Current report (foreign)
10:39am
F-6EF
wpe1j t5xejs0l
18 Dec 23
Automatic registration for ADRs (foreign)
5:23pm
6-K
1pjdfd blojvju4c015
1 Dec 23
Current report (foreign)
12:19pm
SC 13G
hyp0zqfllgepqy01
6 Nov 23
MeiraGTx / Sanofi ownership change
7:50am
6-K
gf79dz98d7gxj
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
6-K
okkoh c1bgmpemyqv2
27 Oct 23
Sanofi Enters Next Chapter of Play to Win Strategy
11:33am
6-K
yuoi85et
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am